Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphir in Persistent or Recurrent CTCL
NCT01871727Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2013
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of denileukin diftitox in cutaneous T-cell lymphoma (CTCL), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting Toxicities, Maximum Tolerated Dose and 1 more. Started May 2013; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01871727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871727.